|
AR039209A1
(es)
*
|
2002-04-03 |
2005-02-09 |
Novartis Ag |
Derivados de indolilmaleimida
|
|
JP2005531609A
(ja)
|
2002-06-05 |
2005-10-20 |
ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ |
キナーゼ阻害剤としてのシスインドリル−マレイミド誘導体
|
|
ES2312785T3
(es)
|
2002-06-05 |
2009-03-01 |
Janssen Pharmaceutica Nv |
Pirrolinas sustituidas utiles como inhibidores de quinasa.
|
|
GB0303319D0
(en)
*
|
2003-02-13 |
2003-03-19 |
Novartis Ag |
Organic compounds
|
|
CA2539132A1
(en)
*
|
2003-09-16 |
2005-03-24 |
Garvan Institute Of Medical Research |
Methods for identifying modulators of protein kinase c-epsilon (pkc.epsilon.) and method of treatment of aberrant glucose metabolism associated therewith
|
|
JP2007509185A
(ja)
*
|
2003-10-27 |
2007-04-12 |
ノバルティス アクチエンゲゼルシャフト |
βアミロイド産生および／または凝集と関係がある神経障害および血管障害の処置のためのインドリル−ピロールジオン誘導体
|
|
CA2545340A1
(en)
*
|
2003-11-10 |
2005-05-26 |
Synta Pharmaceuticals, Corp. |
Fused heterocyclic compounds
|
|
WO2005068454A1
(en)
|
2004-01-19 |
2005-07-28 |
Novartis Ag |
Indolylmaleimide derivatives
|
|
GB0401089D0
(en)
*
|
2004-01-19 |
2004-02-18 |
Novartis Ag |
Organic compounds
|
|
US20070232658A1
(en)
*
|
2004-04-08 |
2007-10-04 |
Jurgen Wagner |
Protein Kinase C Inhibitors for the Treatment of Autoimmune Diseases and of Transplant Rejiction
|
|
GB0410713D0
(en)
|
2004-05-13 |
2004-06-16 |
Novartis Ag |
Organic compounds
|
|
JP5289769B2
(ja)
|
2004-12-08 |
2013-09-11 |
ヨハネス、グーテンベルク−ウニフェルジテート、マインツ |
３−（インドリル）−４−アリールマレイミド誘導体および脈管形成阻害剤としてのそれらの使用
|
|
GB0504203D0
(en)
*
|
2005-03-01 |
2005-04-06 |
Novartis Ag |
Organic compounds
|
|
GB0507918D0
(en)
|
2005-04-19 |
2005-05-25 |
Novartis Ag |
Organic compounds
|
|
US20080207594A1
(en)
|
2005-05-04 |
2008-08-28 |
Davelogen Aktiengesellschaft |
Use of Gsk-3 Inhibitors for Preventing and Treating Pancreatic Autoimmune Disorders
|
|
GB0511060D0
(en)
|
2005-05-31 |
2005-07-06 |
Novartis Ag |
Organic compounds
|
|
EP2246346B1
(en)
*
|
2005-07-11 |
2012-10-24 |
Novartis AG |
Indolylmaleimide derivatives as protein kinase inhibitors
|
|
CA2963828A1
(en)
|
2005-10-26 |
2007-05-03 |
Novartis Ag |
Novel use of il-1beta compounds
|
|
PT2275103E
(pt)
|
2005-11-21 |
2014-07-24 |
Novartis Ag |
Inibidores de mtor para o tratamento de tumores endócrinos
|
|
GB0601744D0
(en)
|
2006-01-27 |
2006-03-08 |
Novartis Ag |
Organic compounds
|
|
GB0605691D0
(en)
*
|
2006-03-21 |
2006-05-03 |
Novartis Ag |
Organic Compounds
|
|
GB0613162D0
(en)
*
|
2006-06-30 |
2006-08-09 |
Novartis Ag |
Organic compounds
|
|
BRPI0716615A2
(pt)
*
|
2006-08-23 |
2013-10-08 |
Novartis Ag |
Uso de inibidores de pkc em doenças oculares
|
|
EP2102195A1
(en)
*
|
2006-10-20 |
2009-09-23 |
Novartis AG |
Crystal modifications -3- (1h-ind0l-3-yl) -4- [2- (4-methyl-piperazin-1-yl) -quinazolin-4-yl]-pyrrole-2, 5-d ione
|
|
MX2009005945A
(es)
*
|
2006-12-07 |
2009-06-17 |
Novartis Ag |
Uso de inhibidores de pkc en transplantes.
|
|
JP2010513386A
(ja)
|
2006-12-19 |
2010-04-30 |
ノバルティス アーゲー |
キナーゼ阻害剤としてのインドリルマレイミド誘導体
|
|
US20100093749A1
(en)
*
|
2007-03-09 |
2010-04-15 |
Novartis Ag |
Compounds
|
|
WO2008145664A1
(en)
|
2007-05-29 |
2008-12-04 |
Novartis Ag |
New indications for anti- il-i-beta therapy
|
|
JP2010540920A
(ja)
|
2007-09-27 |
2010-12-24 |
ノバルティス アーゲー |
薬物モニタリングアッセイ
|
|
JP2011515068A
(ja)
|
2007-11-08 |
2011-05-19 |
ノバルティス アーゲー |
慢性／硬化性同種移植腎症に対する遺伝子発現シグネチャー
|
|
EP2217231B1
(en)
*
|
2007-12-05 |
2011-11-30 |
Johannes Gutenberg-Universität Mainz |
Use of 3-(indolyl)- or 3-(azaindolyl)-4-arylmaleimide derivatives in leukemia management
|
|
US8268834B2
(en)
|
2008-03-19 |
2012-09-18 |
Novartis Ag |
Pyrazine derivatives that inhibit phosphatidylinositol 3-kinase enzyme
|
|
CA2767616A1
(en)
|
2009-07-09 |
2011-01-13 |
The Scripps Research Institute |
Gene expression profiles associated with chronic allograft nephropathy
|
|
RU2441000C2
(ru)
*
|
2009-11-27 |
2012-01-27 |
Общество с ограниченной ответственностью "Молекулярные Технологии" |
4-(1-(4-(4-метоксифенилтио)-2,5-диоксо-2,5-дигидро-1н-пирро-3-ил)-1н-индол-3-ил)бутилкарбамимидотиоат и способ его применения
|
|
EP2343291A1
(en)
|
2009-12-18 |
2011-07-13 |
Johannes Gutenberg-Universität Mainz |
3-(Indolyl)- or 3-(Azaindolyl)-4-arylmaleimide compounds and their use in tumor treatment
|
|
EP2338486A1
(en)
|
2009-12-18 |
2011-06-29 |
Johannes Gutenberg-Universität Mainz |
3-(indolyl)- or 3-(azaindolyl)-4-arylmaleimide derivatives for use in the treatment of colon and gastric adenocarcinoma
|
|
US8791100B2
(en)
|
2010-02-02 |
2014-07-29 |
Novartis Ag |
Aryl benzylamine compounds
|
|
CA2795456A1
(en)
*
|
2010-03-30 |
2011-10-06 |
Novartis Ag |
Pkc inhibitors for the treatment of b-cell lymphoma having chronic active b-cell-receptor signalling
|
|
UA112517C2
(uk)
|
2010-07-06 |
2016-09-26 |
Новартіс Аг |
Тетрагідропіридопіримідинові похідні
|
|
EP2474541A1
(en)
|
2010-12-23 |
2012-07-11 |
Johannes- Gutenberg-Universität Mainz |
Conjugated 3-(indolyl)- and 3-(azaindolyl)-4-arylmaleimide compounds and their use in tumor treatment
|
|
CN102153605B
(zh)
*
|
2011-03-02 |
2014-02-19 |
福建省微生物研究所 |
一种咪唑立宾的提纯方法
|
|
UY34072A
(es)
*
|
2011-05-17 |
2013-01-03 |
Novartis Ag |
Derivados sustituidos de indol
|
|
EP2723740A1
(en)
|
2011-06-27 |
2014-04-30 |
Novartis AG |
Solid forms and salts of tetrahydro-pyrido-pyrimidine derivatives
|
|
GB201111427D0
(en)
*
|
2011-07-05 |
2011-08-17 |
Amakem Nv |
Novel bisindolylmaleimides, pan-pkc inhibitors
|
|
ES2548414T3
(es)
|
2011-07-08 |
2015-10-16 |
Novartis Ag |
Novedosos derivados de pirrolo pirimidina
|
|
WO2013037390A1
(en)
|
2011-09-12 |
2013-03-21 |
Sanofi |
6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
|
|
EP2567959B1
(en)
|
2011-09-12 |
2014-04-16 |
Sanofi |
6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
|
|
US8846712B2
(en)
|
2011-09-12 |
2014-09-30 |
Sanofi |
6-(4-hydroxy-phenyl)-3-styryl-1H-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
|
|
EP2760862B1
(en)
|
2011-09-27 |
2015-10-21 |
Sanofi |
6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
|
|
WO2013057711A1
(en)
|
2011-10-21 |
2013-04-25 |
Novartis Ag |
Quinazoline derivatives as pi3k modulators
|
|
US20140348848A1
(en)
|
2011-12-02 |
2014-11-27 |
Dhananjay Kaul |
Anti-il-1beta (interleukin-1beta) antibody-based prophylactic therapy to prevent complications leading to vaso-occlusion in sickle cell disease
|
|
ES2661510T3
(es)
|
2011-12-15 |
2018-04-02 |
Novartis Ag |
Uso de inhibidores de la actividad o función de PI3K
|
|
IN2014CN04174A
(enExample)
|
2011-12-22 |
2015-09-04 |
Novartis Ag |
|
|
EP2794594A1
(en)
|
2011-12-22 |
2014-10-29 |
Novartis AG |
Quinoline derivatives
|
|
EP2847191B1
(en)
|
2012-05-09 |
2016-06-15 |
Sanofi |
Substituted 6-(4-hydroxy-phenyl)-1h-pyrazolo[3,4-b]pyridine derivatives as kinase inhibitors
|
|
BR112015009214A2
(pt)
|
2012-11-07 |
2017-07-04 |
Novartis Ag |
derivados de indol substituído
|
|
TW201422625A
(zh)
|
2012-11-26 |
2014-06-16 |
Novartis Ag |
二氫－吡啶并－□衍生物之固體形式
|
|
RU2674995C2
(ru)
*
|
2012-11-29 |
2018-12-14 |
Новартис Аг |
Фармацевтические комбинации
|
|
US9724331B2
(en)
|
2012-12-10 |
2017-08-08 |
Centogene Ag |
Use of maleimide derivatives for preventing and treating leukemia
|
|
US9993463B2
(en)
|
2012-12-10 |
2018-06-12 |
Centogene Ag |
Use of maleimide derivatives for preventing and treating cancer
|
|
WO2014128612A1
(en)
|
2013-02-20 |
2014-08-28 |
Novartis Ag |
Quinazolin-4-one derivatives
|
|
WO2014174478A1
(en)
|
2013-04-26 |
2014-10-30 |
Novartis Ag |
Pharmaceutical combinations of a pkc inhibitor and a c-met receptor tyrosine kinase inhibitor
|
|
KR20160060100A
(ko)
|
2013-09-22 |
2016-05-27 |
칼리토르 사이언시즈, 엘엘씨 |
치환된 아미노피리미딘 화합물 및 이용 방법
|
|
US9512084B2
(en)
|
2013-11-29 |
2016-12-06 |
Novartis Ag |
Amino pyrimidine derivatives
|
|
US9399637B2
(en)
|
2014-03-28 |
2016-07-26 |
Calitor Sciences, Llc |
Substituted heteroaryl compounds and methods of use
|
|
AU2014391610B2
(en)
|
2014-04-24 |
2018-01-25 |
Novartis Ag |
Pyrazine derivatives as phosphatidylinositol 3-kinase inhibitors
|
|
CA2945212A1
(en)
|
2014-04-24 |
2015-10-29 |
Novartis Ag |
Amino pyrazine derivatives as phosphatidylinositol 3-kinase inhibitors
|
|
KR20160145780A
(ko)
|
2014-04-24 |
2016-12-20 |
노파르티스 아게 |
포스파티딜이노시톨 3-키나제 억제제로서의 아미노 피리딘 유도체
|
|
US11104951B2
(en)
|
2014-05-22 |
2021-08-31 |
The Scripps Research Institute |
Molecular signatures for distinguishing liver transplant rejections or injuries
|
|
US10443100B2
(en)
|
2014-05-22 |
2019-10-15 |
The Scripps Research Institute |
Gene expression profiles associated with sub-clinical kidney transplant rejection
|
|
EP3146077A4
(en)
|
2014-05-22 |
2018-05-02 |
The Scripps Research Institute |
Tissue molecular signatures of kidney transplant rejections
|
|
JO3589B1
(ar)
|
2014-08-06 |
2020-07-05 |
Novartis Ag |
مثبطات كيناز البروتين c وطرق استخداماتها
|
|
KR20180037975A
(ko)
|
2015-08-14 |
2018-04-13 |
노파르티스 아게 |
포도막 흑색종을 치료하기 위한 mdm2 억제제
|
|
EP3347097B1
(en)
|
2015-09-11 |
2021-02-24 |
Sunshine Lake Pharma Co., Ltd. |
Substituted aminopyrimidine derivatives as modulators of the kinases jak, flt3 and aurora
|
|
EP3187495A1
(en)
|
2015-12-30 |
2017-07-05 |
Johannes Gutenberg-Universität Mainz |
3-(5-fluoroindolyl)-4-arylmaleimide compounds and their use in tumor treatment
|
|
SG11201806628UA
(en)
*
|
2016-02-03 |
2018-09-27 |
Galderma Res & Dev |
New bi-aromatic propynyl compounds, pharmaceutical and cosmetic compositions containing them and uses thereof
|
|
WO2018175302A1
(en)
|
2017-03-20 |
2018-09-27 |
Sienna Biopharmaceuticals, Inc. |
Polymer conjugates targeting c-src with reduced exposure
|
|
WO2018175340A1
(en)
|
2017-03-20 |
2018-09-27 |
Sienna Biopharmaceuticals, Inc. |
Reduced exposure conjugates modulating therapeutic targets
|
|
WO2019099311A1
(en)
|
2017-11-19 |
2019-05-23 |
Sunshine Lake Pharma Co., Ltd. |
Substituted heteroaryl compounds and methods of use
|
|
EP3740468B1
(en)
|
2018-01-20 |
2025-12-31 |
Sunshine Lake Pharma Co., Ltd. |
Substituted Aminopyrimidine Compounds and Methods of Use
|
|
CN110551103B
(zh)
*
|
2018-05-30 |
2022-08-23 |
北京大学深圳研究生院 |
一种jak3选择性抑制剂
|
|
JP7137696B2
(ja)
|
2019-05-14 |
2022-09-14 |
プロヴェンション・バイオ・インコーポレイテッド |
１型糖尿病を予防するための方法および組成物
|
|
CN113840821A
(zh)
|
2019-05-23 |
2021-12-24 |
诺华股份有限公司 |
Btk抑制剂的晶型
|
|
KR20230092863A
(ko)
|
2020-06-11 |
2023-06-26 |
프로벤션 바이오, 인코포레이티드 |
제1형 당뇨병을 예방하기 위한 방법 및 조성물
|
|
MX2023013851A
(es)
|
2021-05-24 |
2023-12-08 |
Provention Bio Inc |
Metodos para el tratamiento de diabetes tipo 1.
|
|
CN120817930B
(zh)
*
|
2025-06-30 |
2026-03-31 |
湖南科技职业学院 |
吲哚马来酰亚胺衍生物及其应用
|